Caribou Biosciences Inc (CRBU) FinancialsCRBUCaribou Biosciences Inc

Evaluating the bottom line, Caribou Biosciences, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1690.39%, while the net margin is -1619.88%. These profitability ratios, combined with a Return on Equity (ROE) of -78.27%, provide a clear picture of how effectively CRBU converts its operational activities into shareholder value.

In the context of the broader market, CRBU competes directly with industry leaders such as ELTX and TIL. With a market capitalization of $46.83M, it holds a leading position in the sector. When comparing efficiency, CRBU's gross margin of 100.00% stands against ELTX's N/A and TIL's N/A. Such benchmarking helps identify whether Caribou Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Caribou has shown a gross margin of 100% in recent quarters, but it has also reported substantial net losses, with a net income of -$25,085,000 in Q1 2026 and -$24,282,000 in Q2 2026. This indicates ongoing financial struggles despite some revenue growth.